According to Medtech's announcement, it achieved revenue of 160 million yuan in the first half of 2026, an increase of 13.42% over the previous year. Sales of safe infusion products have been stable, blood purification revenue has declined year-on-year, orders in hand are sufficient, and revenue from pharmaceutical combinations has increased significantly. During the reporting period, 44 new patent applications were submitted, and 67 new patent authorizations were granted; the share repurchase was completed, with a total repurchase of 1.8951 million shares, accounting for 1.14% of the total share capital, and a total payment of 3.0713 million yuan; based on the 2025 annual results, a cash dividend of 2.5 yuan was distributed to all shareholders for every 10 shares, for a total of 404.33 million yuan.

According to Medtech's announcement, it achieved revenue of 160 million yuan in the first half of 2026, an increase of 13.42% over the previous year. Sales of safe infusion products have been stable, blood purification revenue has declined year-on-year, orders in hand are sufficient, and revenue from pharmaceutical combinations has increased significantly. During the reporting period, 44 new patent applications were submitted, and 67 new patent authorizations were granted; the share repurchase was completed, with a total repurchase of 1.8951 million shares, accounting for 1.14% of the total share capital, and a total payment of 3.0713 million yuan; based on the 2025 annual results, a cash dividend of 2.5 yuan was distributed to all shareholders for every 10 shares, for a total of 404.33 million yuan.